Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
Familial amyloidosis
MeSH D028226 - familial amyloidosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D000686:
Amyloidosis
42 Companies
6 Drugs
$
Success rate
D008661:
Inborn errors metabolism
8 Companies
18 Drugs
$
Success rate
D028226:
Familial amyloidosis
1 Company
1 Drug
$
Success rate
D028227:
Familial amyloid neuropathies
2 Companies
2 Drugs
$
Success rate
D028243:
Familial cerebral amyloid angiopathy
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Alnylam Pharmaceuticals
Patisiran
Onpattro
2018-08-27
$307.056 M
Q3/23-Q2/24
Clinical Trials
Historical Success Rate
Phase 1
0
%
0/0
Phase 2
100
%
1/1
Phase 3
50
%
2/4
Approved:
1
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Alnylam Pharmaceuticals
Patisiran
,
Sodium chloride
,
Revusiran
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use